Introduction {#s1}
============

Impairments in dopaminergic neurotransmission in the basal ganglia are a hallmark of Parkinson disease (PD), the second most common neurodegenerative disease. Replacement of dopamine has been the cornerstone of treatment for PD. Because dopamine itself does not cross the blood-brain barrier (BBB), its immediate precursor levodopa ([l]{.smallcaps}-3,4-dihydroxphenylalanine, [l]{.smallcaps}-DOPA) is administered since it crosses the BBB (Hornykiewicz, [@B66]; Cotzias et al., [@B32]; Birkmayer and Hornykiewicz, [@B12]). Although purified levodopa was first ingested by mouth in 1913 (Roe, [@B126]), it was first used for medical treatment by intravenous (IV) rather than oral administration (Pare and Sandler, [@B113]; Birkmayer and Hornykiewicz, [@B12]).

Oral levodopa has become the preferred method of treatment clinically, but IV levodopa administration still holds advantages over the oral form for some purposes. First, the rapid administration of IV levodopa is often necessary for certain study designs, including those focused on the pharmacokinetics and pharmacodynamics of the drug. Additionally, the IV route leads to more predictable plasma levodopa concentration because oral medications have highly variable absorption characteristics, especially in PD patients (Bushmann et al., [@B26]), with differences in absorption based on sex and age (Robertson et al., [@B124]; Kompoliti et al., [@B76]). IV administration also permits researchers to keep brain levodopa concentrations constant while assessing physiological responses over time. Recent years have seen increasing interest in potential benefits of continuous dopaminergic stimulation in the treatment of PD (Jenner et al., [@B70]). Continuous stimulation helps avoid wearing off of motor benefit during levodopa nadirs, and there is also some evidence that it may reduce the risk of, or mitigate, dyskinesias and other peak-dose side effects. Thus, IV levodopa may prove useful for human studies investigating the pathophysiology of continuous vs. pulsatile dopaminergic stimulation in humans. Finally, IV levodopa is sometimes used clinically in patients who cannot tolerate oral medications, such as PD patients during surgery or on total parenteral nutrition.

Current U.S. FDA regulations focus heightened scrutiny on research in which drugs are delivered by a route for which the drug has not been approved. Predictably, in addition to any safety benefits, the heightened scrutiny has created practical obstacles to research with IV levodopa, as described for instance by Rascol et al. ([@B121], p. 250). Specifically, an IND (Investigational New Drug) application must be submitted if the risks of IV administration significantly exceed those of oral levodopa \[§21 CFR 312.2(b)(iii)\]. Therefore, the overall goal of this paper is to determine whether or not IV levodopa carries risks greater than oral administration by compiling a literature review that comprehensively summarizes the human experience with intravenously administered levodopa. We tabulate the extent of human exposure, side effects, benefits, and efficacy. We also summarize pharmacokinetic (PK) and pharmacodynamic (PD) parameters from these studies. These data should help inform decisions about whether IV administration of levodopa requires an IND.

Methods {#s2}
=======

The authors searched MEDLINE and OVID, reviewed selected books, searched toxicity databases, and followed references cited in those sources. Articles written completely in languages other than English, French, German, Italian, Spanish, or Portuguese were excluded. Search terms included (levodopa/L-dopa/DOPA) AND (intravenous/intravascular/infusion/injection/i.v.); limit to humans; search date through May, 2015. Studies using oral or intraduodenal l-DOPA administration were excluded except for PK/PD studies cited in **Table 2**. Studies in which IV levodopa was always coadministered with monoamine oxidase inhibitors (MAOIs) or catechol-O-methyltransferase (COMT) inhibitors were excluded. Levodopa methyl ester (Juncos et al., [@B72]) and d,l-DOPA (Pare and Sandler, [@B113]) were included, but PK/PD calculations were corrected for the difference in molecular weights. Co-administered drugs were reported if included by the authors.

We recorded total dose and maximum infusion rate. We also recorded pharmacokinetic (PK) and pharmacodynamic (PD) parameters where available, including steady state volume of distribution (VOD), clearance, distribution half life (*t*~½α~), elimination half life (*t*~½~ or *t*~β~), *E*~*max*~, and *EC*~50~. Reported data were used to calculate any missing PK parameters where possible. Additionally, any reports on efficacy were noted. Side effect frequency was recorded if reported. The number of subjects and subject conditions (Parkinson disease, other disease states or healthy volunteers) were recorded for each study. Average PK parameters were calculated across studies, weighted by the number of subjects.

Results {#s3}
=======

One hundred forty-two articles reporting intravenous levodopa administration were identified. Most subjects with parkinsonism were diagnosed with idiopathic PD, but some studies reported a variety of etiologies including postencephalitic and vascular parkinsonism and PSP. PD patients differed in their history of prior drug treatment before the studies with conditions including *de novo*, fluctuating, on-off, and stable. Some subjects were treated with levodopa for conditions other than PD (see Table [1](#T1){ref-type="table"}: Patient Populations and Response Parameters), including other movement disorders (dystonia, progressive supranuclear palsy \[PSP\], neuroleptic malignant syndrome \[NMS\], primary psychiatric disorders (schizophrenia, mood disorders, personality disorders), endocrine disorders (diabetes mellitus, essential obesity, hypopituitarism), hepatic disease (alcoholic cirrhosis, steatohepatitis, hepatic encephalopathy), cardiac valvular disease, and asthma. Healthy controls were also included in some studies.

###### 

**Patient populations and response parameters**.

  **Patient populations**                                    **Response parameters**
  ---------------------------------------------------------- ------------------------------------------------------------------------------
  Healthy volunteers                                         Vital signs:
  Movement disorders:                                           Heart rate, blood pressure,
     Parkinson\'s (*de novo*, stable, fluctuators, on-off)      temperature, respirations
                                                             Cardiovascular:
     Progressive supranuclear palsy                             ECG
     Parkinson\'s disease psychosis                             Cerebral blood flow
     Carcinoma of the rectum                                 Renal:
     Stereotactic surgery                                       Urine flow
     Post-menopausal women                                      Urinary sodium excretion
     Tourette syndrome/tic disorders                            Potassium excretion
  Asthma                                                        Plasma renin activity
  Schizophrenia                                                 Renal plasma flow
  Mood disorders:                                            Metabolism:
     Mild to moderate depression                                Urinary metabolite excretion
     Treatment-resistant depression                             Cerebral metabolism
     Bipolar depression                                         Plasma metabolites
     Cyclothymic disorder                                    CSF amino-acid composition
  Borderline personality disorder                            PD motor improvement
  Neuroleptic malignant syndrome                                Unified Parkinson\'s disease rating scale (UPDRS), walking, tapping, etc.
  Hepatic disorders:                                            Dyskinesias
     Alcoholic cirrhosis                                     Tic improvement
     Steatohepatitis                                         Neuropsychiatric:
     Hepatic encephalopathy                                     Cognition
  Endocrine disorders:                                          Mood
     Diabetes mellitus                                          Behavior
     Essential obesity                                          Psychosis
     Hypopituitarism                                            Dementia
  Cardiovascular disease:                                       EEG (including REM sleep EEG)
     Atrial septal defect                                    Endocrine:
     Rheumatic valvular disease                                 Prolactin, HGH, ACTH, LH, vasopressin

*Subject populations given IV levodopa and responses to drug measured in studies listed in **Table 3***.

Pharmacokinetic data were reported for a total of 251 human subjects (see Table [2](#T2){ref-type="table"}: Pharmacokinetics of Levodopa). Co-administration of a peripheral decarboxylase inhibitor (PDI) lowered the clearance and increased the elimination half-life of intravenously administered levodopa, while there was no notable effect of PDIs on volume of distribution. Additional PK data are available from studies that gave levodopa by other routes (Sasahara et al., [@B130]; Poewe, [@B116]; Muhlack et al., [@B93]; LeWitt et al., [@B77]), and several studies report the bioavailability of oral doses relative to IV administration (Sasahara et al., [@B131]; Robertson et al., [@B124]; Kompoliti et al., [@B76]).

###### 

**Pharmacokinetics of levodopa**.

  **References**                                                                              **Patient group**       **Clearance**   **Volume of distribution**   **Elimination half-life**   **Distribution half-life**   **Oral bioavailability**                                                     
  ------------------------------------------------------------------------------------------- ----------------------- --------------- ---------------------------- --------------------------- ---------------------------- -------------------------- -------- ---- -------- -------------------------- ------
  Birkmayer et al., [@B8]                                                                     PD                      50              1.61                         50                          2.44                         50                         1.05                                              
  Bredberg et al., [@B20]                                                                     Fluctuating             5               0.37                                                                                                                                                               
  Chan et al., [@B28]                                                                         *De novo*               12              0.36                         12                          0.63                         12                         2.25     12   0.17                                
                                                                                              Chronic                 12              0.35                         12                          0.49                         12                         1.47     12   0.17                                
  Durso et al., [@B35]                                                                        "Slow" CD absorption                                                                                                          5                          1.18                                              
                                                                                              "Rapid" CD absorption                                                                                                         4                          1.15                                              
  Fabbrini et al., [@B37]                                                                     *De novo*               4               0.13                         4                           0.26                         4                          1.44                                              
                                                                                              Stable                  6               0.11                         6                           0.22                         6                          1.41                                              
                                                                                              Wearing-Off             6               0.13                         6                           0.30                         6                          1.67                                              
                                                                                              On-off                  12              0.13                         12                          0.30                         12                         1.54                                              
  Hardie et al., [@B58][^a^](#TN1){ref-type="table-fn"}                                       Fluctuating             7               1.14                         7                           2.63                         7                          1.60     7    0.13                                
  Gancher et al., [@B47][^b^](#TN2){ref-type="table-fn"}                                      *De novo*               5               0.34                         5                           0.56                         5                          1.70     5    0.10                                
                                                                                              Stable                  4               0.33                         4                           0.62                         4                          1.80     4    0.11                                
                                                                                              Fluctuating             11              0.32                         11                          0.65                         11                         2.00     11   0.10                                
  Nutt et al., [@B108]                                                                        2 h IV                  7               0.55                         7                           0.67                         7                          1.38     7    0.07                                
  (all PD, fluctuating)                                                                       2 h IV + PDI            7               0.30                         7                           0.80                         7                          2.01     7    0.11                                
                                                                                              ≥20 h IV                4               0.52                         4                           0.88                         4                          1.19     4    0.11                                
                                                                                              ≥20 h IV + PDI          4               0.28                         4                           1.09                         4                          2.60     4    0.33                                
  Nutt et al., [@B109]                                                                        *De novo*               8               0.44                         8                           0.75                         8                          1.60                                              
                                                                                              Stable                  12              0.42                         12                          0.75                         12                         1.70                                              
                                                                                              Fluctuating             9               0.39                         9                           0.63                         9                          1.50                                              
  Poewe, [@B116][^e^](#TN5){ref-type="table-fn"}                                              PD                                      1.40                                                     3.00                                                    1.50          0.09                                
  Roberts et al., [@B123][^c^](#TN3){ref-type="table-fn"}, [^d^](#TN4){ref-type="table-fn"}   Healthy                 8               0.37                         8                           1.13                         8                          2.15                                              
                                                                                              Healthy + selegine      8               0.37                         8                           2.01                         8                          3.78                                              
  Robertson et al., [@B124][^c^](#TN3){ref-type="table-fn"}                                   Healthy elderly         9               0.85                         9                           1.01                         9                          0.82                   9                          0.63
                                                                                              Healthy young           8               1.40                         8                           1.65                         8                          0.82                   8                          0.41
                                                                                              Healthy elderly + PDI   8               0.35                         8                           0.62                         8                          1.23                   8                          0.85
                                                                                              Healthy young + PDI     8               0.56                         8                           0.93                         8                          1.16                   8                          0.86
  Sasahara et al., [@B131][^f^](#TN6){ref-type="table-fn"}                                    PD                      5               1.38                         5                           1.29                         5                          0.65                   5                          0.33
  Stocchi et al., [@B140]                                                                     Intravenous bolus       6               0.97                         6                           0.96                         6                          0.83                                              
  (all "on-off")                                                                              Intravenous infusions   2               0.63                         2                           0.82                         2                          0.90                                              
                                                                                              Total *n*               212                                          242                                                      251                                 73            16 (PDI) 22 (no PDI)       
                                                                                              Weighted mean                           0.719 L/kg/h                                             1.18 L/kg                                               1.50 h        0.14 h   0.86 (PDI) 0.48 (no PDI)   

*Summary of pharmacokinetic parameters with weighted means*.

*Assumed mean weight to be 70 kg for VOD*.

*Values read from graphs*.

*Half-life estimated from relationship: clearance = (ln 2 ^\*^ VOD)/ elim. T1/2*.

*Assumed mean weight to be 70 kg for clearance*.

*From a table with no additional data provided; not included in weighted mean calculations of pharmacokinetic parameters*.

*VOD estimated from relationship: clearance = (ln 2 ^\*^ VOD)/ elim. T1/2*.

The pharmacodynamic data (see Table [3](#T3){ref-type="table"}: Reports of Human Experience with IV Levodopa) represent a total of 2760 human subjects, with a significant variety of patient groups and a multitude of response parameters (see Table [1](#T1){ref-type="table"}). No side effects were reported for 1260 subjects. The highest total IV dose was 4320 mg in 1 day, given to a patient with idiopathic PD and carcinoma of the retina. The patient reported no adverse effects at this dose. The highest reported single bolus dose was 200 mg, and the highest infusion rate was 5.0 mg/kg/h.

###### 

**The human experience with IV levodopa**.

  **References**                       ***N***      **Diagnosis**                                                                                                                                          **PDI**                               **Concomitant drugs**                                                                                         **Total dose**                                                                                                                                     **Maximum rate**                                                                                                                        **Side effects/comments**
  ------------------------------------ ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------- ------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abramsky and Goldschmidt, [@B1]      4            Acute hepatic encephalopathy in cirrhotic patients with gastrointestinal bleeding                                                                      None mentioned                        None mentioned                                                                                                For several days (between 3 and 5 days depending on the patient)                                                                                   600--1200 mg/day                                                                                                                        Levodopa was administered intravenously with striking and rapid improvement of the comatose state. Within 2--5 h the patients had recovered their normal mental state
  Aebert, [@B2]                        11           10 PD, 1 post-encephalitis lethargica                                                                                                                  None mentioned                        None mentioned                                                                                                75--1375 mg                                                                                                                                        75--100 mg/10--15 min                                                                                                                   No side effects mentioned
  Argyelan et al., [@B3]               15           PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                Not given                                                                                                                                          0.83 mg/kg/h                                                                                                                            No side effects mentioned. Levodopa was associated with increases in learning-related activation in the left dorsal premotor cortex and in the right pre-supplementary motor area. In the former region, there was recovery of the normal activation response by levodopa. In the latter region, there was a treatment-mediated gain of response in that significant learning-related activation was present only when the patients were scanned on levodopa therapy
  Baldy-Moulinier et al., [@B4]        19           Twelve alcoholic hepatic cirrhosis and hepatic encephalopathy; 3 alcoholic hepatic cirrhosis; 3 fatty liver (alcoholic) without cirrhosis; 1 healthy   None mentioned                        None mentioned                                                                                                125 mg                                                                                                                                             125 mg bolus                                                                                                                            No effects on electroencephalogram, electrocardiogram, humeral arterial pressure, rectal temperature, cerebral perfusion or metabolism at this dose
  Bara-Jimenez et al., [@B5]           15           Moderate to advanced PD                                                                                                                                Carbidopa                             KW-6002 (Adenosine A2A receptor antagonist)                                                                   Infusion of "optimal dose levodopa"                                                                                                                725 ± 65 ng/mL                                                                                                                          No side effects mentioned for L-dopa plus placebo. There were no drug-related serious adverse events. Levodopa plus KW-6002 appeared generally safe and well-tolerated
  Baronti et al., [@B6]                9            Moderate to severe PD (III--V)                                                                                                                         Carbidopa                             Terguride (dopamine agonist); domperidone in 4 subjects                                                       Variable, 26--55 mg/h (from 5:00 a.m. until end of day\'s study)                                                                                   55 mg/h                                                                                                                                 No side effects noted for L-dopa alone. For terguride plus levodopa, subjects had mild, transient asymptomatic orthostatic hypotension, headache, nausea, nervousness, drowsiness, light-headedness, and epigastric distress
  Birkmayer and Hornykiewicz, [@B10]   Not given    Not given                                                                                                                                              None mentioned                        None mentioned                                                                                                50--150 mg                                                                                                                                         150 mg                                                                                                                                  No side effects mentioned
  Birkmayer and Hornykiewicz, [@B11]   200          Not given                                                                                                                                              None mentioned                        None mentioned                                                                                                25 mg, once or twice a week, for up to 3 years                                                                                                     "Slow infusion"                                                                                                                         Unclear whether L-dopa was administered without MAO inhibitors or nialamide. Nausea, vomiting and fainting were the major side effects which inversely correlated with the level of benefit
  Birkmayer and Hornykiewicz, [@B10]   132          PD                                                                                                                                                     None                                  MAO inhibitor (Ro-4/2637), caffeine, or euphyllin                                                             50--150 mg infusions twice a week for 2 weeks                                                                                                      150 mg                                                                                                                                  L-dopa caused nausea and vomiting, if combined with MAO inhibitor. Caffeine or Euphyllin could reduce L-dopa side effects
  Birkmayer and Mentasti, [@B13]       15           PD                                                                                                                                                     Ro 4--4602 (benserazide)              None mentioned                                                                                                50 mg                                                                                                                                              50 mg                                                                                                                                   No side effects mentioned. Decarboxylase inhibitor increased the benefit of L-dopa
  Birkmayer, [@B7]                     1            PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                50 mg                                                                                                                                              Not mentioned                                                                                                                           No side effects mentioned
  Birkmayer and Hornykiewicz, [@B9]    20           Parkinsonism (PD, postencephalitic parkinsonism, and vascular parkinsonism)                                                                            None mentioned                        None mentioned                                                                                                Up to 150 mg                                                                                                                                       "slow i.v." Degkwitz et al., [@B34]                                                                                                     No side effects mentioned
  Black et al., [@B15]                 127          55 PD, 20 chronic tic disorders, 52 normal                                                                                                             Carbidopa                             None mentioned                                                                                                2.2 mg/kg                                                                                                                                          1.735 mg/kg /10 min                                                                                                                     In healthy patients at high doses: nausea, vomiting, feeling uncomfortably hot, increased pulse rate. In PD patients at high doses: no side effects. In healthy patients at intermediate doses: nausea, vomiting. In PD patients at intermediate doses, some had dyskinesias but no nausea or vomiting. At low doses: there was some nausea in healthy patients
  Black et al., [@B16],[@B14]          21           PD                                                                                                                                                     Carbidopa                             Tozadenant (SYN115)                                                                                           0.6426 mg/kg                                                                                                                                       2.882 × 10^−5^ × (140--age) mg/kg/min                                                                                                   Carbidopa 200 mg was given by mouth at least an hour before the levodopa infusion began, using the method of Gordon et al. ([@B54]) and a target plasma concentration of 600 ng/ml
  Blanchet et al., [@B17]              8            PD (postmenopausal women with mild to moderate PD)                                                                                                     Carbidopa                             Estradiol                                                                                                     29 ± 4 mg/10 min twice per day                                                                                                                     33 mg/10 min                                                                                                                            The threshold dose of levodopa necessary to provide definite antiparkinsonian efficacy was reduced significantly by 17\[beta\]-estradiol from 29 to 21 mg
  Braun et al., [@B19]                 7            Idiopathic PD                                                                                                                                          Carbidopa                             SKF38393 (selective D-1 agonist) administered orally in double blind, placebo- controlled, crossover design   (10--80 mg/h) × 12 h                                                                                                                               80 mg/h                                                                                                                                 No dyskinesias occurred with levodopa and simultaneous SKF38393 treatment. Dyskinesias at higher, supraoptimal doses. No side effects mentioned for L-Dopa alone: no orthostatic changes in blood pressure; patients remained asymptomatic throughout. Hematological parameters and blood chemistries remained within normal limits
  Bredberg et al., [@B20]              5            PD (advanced)                                                                                                                                          Benserazide                           None mentioned                                                                                                Not given                                                                                                                                          1.5 mg/min                                                                                                                              No side effects mentioned
  Brod et al., [@B21]                  12           PD                                                                                                                                                     Carbidopa                             None                                                                                                          2 mg/kg                                                                                                                                            1 mg/kg/h                                                                                                                               Study compared low doses of carbidopa to higher doses. Side effects mostly related to parkinsonian symptoms associated with lower dose of IV levodopa than the patient\'s usual oral dose
  Bronaugh et al., [@B22]              21           PD (15 idiopathic, 2 secondary to encephalitis lethargic, 2 associated with progressive supranuclear palsy)                                            None mentioned                        None mentioned                                                                                                calculated:30.8--56 μg (for 7 patients, and for 6 patients who were already on 3.0 g/day orally)                                                   7.7--14 μg/4 h on top of an oral dose of 3.0 g/day                                                                                      No side effects mentioned. Percent conjugation of L-dopa and metabolites given
  Bruck et al., [@B23]                 20           10 PD, 10 healthy                                                                                                                                      None mentioned                        None mentioned                                                                                                100 mg for PD, 50 mg for healthy individuals                                                                                                       50--100 mg/20--30 min                                                                                                                   Nausea, lightheadedness, syncope, unpleasant sensation in head and abdomen, and increased blood pressure by 10--20 mmHg
  Bruno and Brigida, [@B24]            18           Schizophrenia                                                                                                                                          None mentioned                        Haloperidol                                                                                                   100--170 mg                                                                                                                                        2 mg/kg/5 min                                                                                                                           No side effects mentioned for L-Dopa alone, only in combination with Haloperidol
  Bruno and Bruno, [@B25]              40           Schizophrenia                                                                                                                                          None mentioned                        20 received haloperidol, 20 received chlorpromazine                                                           2 mg/kg                                                                                                                                            2 mg/kg/5 min                                                                                                                           Neuroleptic-induced parkinsonism improved in both groups. Some improvement in antipsychotic-induced negative symptoms. Some patients developed nausea/vomiting, sweating, warmth/flushing, and dizziness (number not reported). No significant change in pulse or blood pressure
  Camicioli et al., [@B27]             5            PD (idiopathic), functionally independent                                                                                                              Carbidopa                             Methylphenidate (in one trial, compared to levodopa alone)                                                    2 mg/kg                                                                                                                                            2 mg/kg/h                                                                                                                               Apart from bothersome dyskinesias in one patient, patients did not report side effects or difficulties with treatments. No effect on heart rate or diastolic blood pressure, but L-Dopa led to a drop in systolic blood pressure. The drop in systolic blood pressure caused by L-Dopa was reduced when methylphenidate was administered alongside L-Dopa. No changes in mood, anxiety, arousal, or concentration before or after medications. Motor Unified Parkinson\'s Disease Response Scores were improved, as were tapping rates for both sides and both walking steps and rate
  Chan et al., [@B28]                  25           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                2.35 g/day (× 3 days)                                                                                                                              1.6 mg/kg/h (× 2 h × 3 days)                                                                                                            No side effects mentioned
  Chung et al., [@B29]                 14           Idiopathic PD                                                                                                                                          Carbidopa                             Paroxetine                                                                                                    2.0 mg/kg/day × 4 weeks                                                                                                                            1.0 mg/kg/h                                                                                                                             No side effects mentioned. No serious adverse effects
  Chung et al., [@B30]                 22           PD (15 with levodopa-induced dyskinesia)                                                                                                               Carbidopa                             None mentioned                                                                                                2--3 mg/kg                                                                                                                                         1.5 mg/kg/h                                                                                                                             No side effects mentioned
  Davis et al., [@B33]                 10           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                None mentioned: just found "optimal dose rate" Total of 4 consecutive doses at the optimal rate were given, so highest total dose was 4.4 mg/day   1.1 mg/kg/10 min                                                                                                                        Modest worsening of motor scores after levodopa stopped. Patients with unpredictable motor fluctuations have higher requirements for levodopa, both orally and intravenously, compared to those with simple wearing-off phenomena
  Degkwitz et al., [@B34]              ≥22          Psychiatric patients and normal controls                                                                                                               None                                  None mentioned                                                                                                50--350 mg                                                                                                                                         Bolus (at least, ≤ 10 min)                                                                                                              No side effects mentioned
  Durso et al., [@B36]                 8            Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                150 mg bolus                                                                                                                                       150 mg bolus stable isotope-labeled LD/12--15 min                                                                                       No side effects mentioned
  Durso et al., [@B35]                 9            Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                150 mg bolus                                                                                                                                       150 mg bolus ^13^C labeled L-DOPA/12--15 min                                                                                            Average reduction in systolic blood pressure was 22 mmHg (14, 10--40). No prolonged cardiac arrhythmias were noted during infusion or subsequent 6-h monitoring
  Fabbrini et al., [@B37]              28           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                1.5 mg/kg/h for ≥16 h                                                                                                                              1.5 mg/kg/h                                                                                                                             No side effects mentioned
  Fabbrini et al., [@B38]              48           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                19.2 mg/kg                                                                                                                                         2.0 mg/kg/h                                                                                                                             No side effects mentioned
  Fasano et al., [@B40]                66           PD                                                                                                                                                     Benserazide 150 mg IV                 Stimulant ("anfetamino- simile")                                                                              Not stated                                                                                                                                         Not stated                                                                                                                              The authors say, "no side effects were reported" with IV levodopa, whereas chronic oral levodopa dosing (without benserazide) produced side effects in 87% of patients ("psychic disturbances," dyskinesias, nausea, vomiting, and orthostatic hypotension)
  Fasano et al., [@B39]                75           PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                Not stated                                                                                                                                         Not stated                                                                                                                              No side effects mentioned
  Fehling, [@B41]                      25           PD                                                                                                                                                     None                                  None mentioned                                                                                                1.5 mg/kg                                                                                                                                          1.5 mg/kg over 13 min (6.9 mg/kg/h)                                                                                                     Levodopa did not differ from placebo in terms of clinical improvement. Levodopa caused a brief period of nausea in 9 patients and vomiting in 2 patients. Levodopa and placebo did not differ in their effects on blood pressure
  Feigin et al., [@B42]                7            PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                Not given                                                                                                                                          100 mg/h (mean, 67.1 ± 25.6 mg/h)                                                                                                       No side effects mentioned
  Feigin et al., [@B44]                7            PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                Varied                                                                                                                                             100 mg/h                                                                                                                                No side effects mentioned
  Feigin et al., [@B43]                7            PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                Varied                                                                                                                                             100 mg/h                                                                                                                                Levodopa impaired aspects of sequence learning performance in non-demented PD patients; worsening in declarative score during motor sequence learning task suggests levodopa may have negative effects on aspects of cognitive processing linked to target retrieval. Levodopa also decreased activation of occipital association cortex during motor sequence learning
  Friedhoff et al., [@B45]             11           Not given                                                                                                                                              None mentioned                        None mentioned                                                                                                Not given                                                                                                                                          2.5 mg/kg                                                                                                                               No side effects mentioned
  Gancher et al., [@B47]               20           PD (5 *de novo*, 4 stable, 11 fluctuating)                                                                                                             Carbidopa                             None mentioned                                                                                                1--4 mg/kg                                                                                                                                         0.5--0.8 mg/kg/h (lasting 2--5 h) for untreated PD. For treated PD, rate approximated usual oral LD dose                                No side effects reported for IV L-dopa Infusions lasting 2--5 h. After oral levodopa, 2 of 5 *de novo* PD patients became nauseated (without emesis)
  Gancher et al., [@B46]               33           PD (9 *de novo*, 7 stable responders, 17 fluctuating)                                                                                                  Carbidopa                             None mentioned                                                                                                0.8--3.0 mg/kg/h total (0.4 to 1.5 mg/kg/h × 2 h)                                                                                                  1.5 mg/kg/h                                                                                                                             No side effects mentioned
  Gerstenbrand and Pateisky, [@B50]    1            Parkinsonism due to post-encephalitis lethargica                                                                                                       None mentioned                        None mentioned                                                                                                200 mg                                                                                                                                             100 mg/20--40 min                                                                                                                       Increased systolic blood pressure by 10 mmHg, mild mydriasis
  Gerstenbrand and Prosenz, [@B49]     20           PD, postencephalitic parkinsonism and vascular parkinsonism                                                                                            None mentioned                        Isocarboxazid (MAO inhibitor)                                                                                 50--75 mg/day for a few days, or with a few days interval between injections,. up to 6--8 injections total                                         Not given                                                                                                                               L-dopa side effects included nausea, vomiting, blood pressure instability, and heat sensation. Subjects were pretreated with a MAO inhibitor (isocarboxazid) one tablet bid for 10--14 days
  Gerstenbrand and Pateisky, [@B48]    30           Two with Huntington\'s Disease who had reserpine-induced parkinsonism; remaining subjects had postencephalitic parkinsonism, vascular or PD            None mentioned                        MAO inhibitors                                                                                                25--200 mg                                                                                                                                         100--200 mg/20--30 min ("infusion"), 25--75 mg/5 min ("injection"), 100 mg po                                                           L-dopa side effects included: sensation of warmth in head, worsening of chorea in 2 Huntington\'s Disease subjects, nausea/vomiting, change in blood pressure beyond 20 mmHg, vertigo, syncope, unpleasant sensation in head and abdomen, and urge to urinate. Subjects underwent 14 days of pretreatment with MAO-inhibitors
  Gillin et al., [@B51]                10           Mild to moderate depression (4 bipolar depression, 4 unipolar affective disorder, 1 cyclothymic personality, 1 borderline personality)                 Carbidopa                             None mentioned                                                                                                25--50 mg                                                                                                                                          50 mg/2 min                                                                                                                             Pre-REM infusions of L-dopa delayed the onset of REM sleep while infusion at REM onset shortened the length of the REM period. No detectable mood or side effects were noted except that three subjects had non-symptomatic reductions in blood pressure without change in pulse rate 5--25 min following the infusion
  Goetz et al., [@B52]                 5            PD w/daily visual hallucinations                                                                                                                       Carbidopa                             None mentioned                                                                                                6 mg/kg (1.5 mg/kg/h × 4 h)                                                                                                                        1.5 mg/kg/h                                                                                                                             The authors tried to intentionally produce hallucinations in patients who had daily hallucinations with their usual treatment at home. IV doses were added to their oral medications. No patients developed hallucinations even though baseline dyskinesias persisted during the infusions
  Goldstein et al., [@B53]             6            Healthy                                                                                                                                                None mentioned                        None mentioned                                                                                                99--118.8 μg/kg (0.33 μg/min/kg × 5--6 h)                                                                                                          0.33 μg/min/kg                                                                                                                          No side effects mentioned. Authors suggest an enzymatic gut-blood barrier for detoxifying exogenous dopamine and delimiting autocrine/paracrine effects of endogenous dopamine generated in a "third catecholamine system"
  Gordon et al., [@B54]                6            Healthy                                                                                                                                                Carbdiopa                             None mentioned                                                                                                Infusion over 90 min (total dose estimated at \~1100 mg)                                                                                           Not given                                                                                                                               No significant side effects; none of the side effects were above 1 (mild). Side effects included cold hands, mild irritability, headaches, nausea, stomach aches, but there were no significant differences between side effects reported by subjects on levodopa and those with placebo infusions
  Gragnoli et al., [@B55]              25           8 healthy; 8 Diabetes Mellitus; 9 essential obesity                                                                                                    None mentioned                        None mentioned                                                                                                Not clear, possibly 1.5 mg/kg                                                                                                                      1.5 mg/kg/10 min                                                                                                                        None of the subjects suffered nausea or showed other signs of intolerance, or significant variations in blood pressure during the experiment. In diabetics and obese subjects, IV L-dopa causes a less marked human growth hormone increase than in control subjects, with diabetics having more of an increase than obese subjects
  Gründig et al., [@B56]               14           9 PD, 5 normal                                                                                                                                         None mentioned                        None mentioned                                                                                                50 mg (control) to 100 mg                                                                                                                          100 mg                                                                                                                                  No side effects mentioned
  Hardie et al., [@B57]                20           Idiopathic PD                                                                                                                                          Carbidopa or benserazide              Apomorphine (dopaminergic agonist)                                                                            up to 1500 mg/day                                                                                                                                  80 mg/h                                                                                                                                 Dystonia and chorea. 4 patients experienced significant sleep benefit
  Hardie et al., [@B58]                7            PD (on-off fluctuators)                                                                                                                                PDI used but not specified            None mentioned                                                                                                1280 mg (up to 16 h)                                                                                                                               32--80 mg/h                                                                                                                             No side effects mentioned
  Hartvig et al., [@B59]               8            Healthy                                                                                                                                                1 subject given benserazide           None mentioned                                                                                                5.5 mg or 11 mg                                                                                                                                    10 mg bolus                                                                                                                             No side effects mentioned
  Hashizume et al., [@B60]             6            Healthy                                                                                                                                                None mentioned                        None mentioned                                                                                                25 mg bolus                                                                                                                                        25 mg (bolus in 20 mL saline)                                                                                                           No nausea (except for one patient who was given oral levodopa); authors suggest that L-dopa undergoes decarboxylation and sulfation continuously even when administered intravenously
  Henry et al., [@B61]                 13           Depression, otherwise healthy                                                                                                                          Carbidopa                             None mentioned                                                                                                50 mg (after a week\'s interval 6 pts got iv 50 mg DOPS or 100 mg L-DOPA without carbidopa)                                                        50 mg/5 min                                                                                                                             No nausea, vomiting, hypertension, or "other untoward side effects" The study was designed to "avoid such peripheral side effects by pretreating the patients with carbidopa." IV levodopa was associated with reduced learning compared with chronic oral treatment and placebo infusions. No significant changes were found in heart rate/rhythm or blood pressure between levodopa and placebo
  Hirano et al., [@B62]                11           PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                Not given                                                                                                                                          0.56 mg/kg/h                                                                                                                            No side effects mentioned
  Hirschmann and Mayer, [@B63]         10           PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                25--50 mg                                                                                                                                          50 mg                                                                                                                                   "No measurable, problematic side effects on the heart or circulation occurred with a slow IV injection of 25--50 mg"
  Hirschmann and Mayer, [@B64]         31           25 PD, 6 dystonia                                                                                                                                      None                                  MAO inhibitor                                                                                                 25--50 mg; 25 mg/day for 21 days; proceeded to year-long weekly and then monthly injections of unspecified amount                                  Not stated                                                                                                                              No side effects mentioned
  Horai et al., [@B65]                 1            PD                                                                                                                                                     Stopped                               None mentioned                                                                                                100 mg/h × 19 days                                                                                                                                 100 mg/h                                                                                                                                Total dose ≈ 45,600mg. No side effects mentioned
  Ingvarsson, [@B67]                   3            depression: long-standing, refractory (diagnosis unclear)                                                                                              None mentioned                        None mentioned                                                                                                10--50 mg/day for weeks                                                                                                                            50 mg/10 min                                                                                                                            In one case, a sudden improvement in a concomitant asthmatic stridor was observed. "Depression" and "physical symptoms" improved in patients who were classified as depressed but may have had PD as well
  Ingvarsson, [@B68]                   9            Not given                                                                                                                                              None mentioned                        None mentioned                                                                                                50 mg iv                                                                                                                                           50 mg                                                                                                                                   IV levodopa "abolishes asthmatic stridor"
  Jaffe et al., [@B69]                 6            PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                ≥2 h (at least 300 mg)                                                                                                                             2.5 mg/min                                                                                                                              One subject had mild dyskinesia. IV infusion of levodopa can affect the electroretinogram in patients with PD, indicating that the human retina is sensitive to changes in the systemic levels of levodopa and that this drug or its metabolite cross the blood-retinal barrier
  Juncos et al., [@B72]                7            Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                24 h/day × 6--13 days                                                                                                                              \~1.5 mg/kg /10 min (corrected for MW of L-Dopa instead of MW of L-Dopa methyl ester (LDME))                                            Motor fluctuations were markedly reduced with IV LDME. All patients noted an improvement in their condition during LDME treatment; reported benefits included improved sleep, attenuation of early morning akinesia or dystonia. There was no clinical or laboratory evidence of LDME toxicity
  Juncos et al., [@B71]                12           PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                1.6 mg/kg                                                                                                                                          7.1 ± 7.6 mg/h                                                                                                                          Dyskinesia
  Ko et al., [@B73]                    14           PD                                                                                                                                                                                                                                                                                                         Not given                                                                                                                                          Not given, but see note                                                                                                                 No side effects mentioned. Reportedly used same protocol as Mure et al. ([@B94]) and Hirano et al. ([@B62])
  Kobari et al., [@B74]                15           9 PD, 6 PSP (progressive supranuclear palsy)                                                                                                           None mentioned                        None mentioned                                                                                                1 mg/kg                                                                                                                                            2 mg/kg/h                                                                                                                               No significant changes were noted in local cerebral blood flow after the administration of levodopa in patients with PSP
  Kobari et al., [@B75]                34           16 idiopathic PD, 6 PSP (progressive supranuclear palsy), 5 olivopontocerebellar atrophy, 7 arteriosclerotic parkinsonism                              Carbidopa                             None mentioned                                                                                                1 mg/kg                                                                                                                                            2 mg/kg/h                                                                                                                               No significant changes in arterial blood pressure or heart rate. No side effects mentioned. Different patterns of regional cerebral blood flow response to levodopa in PD vs. PSP using xenon-enhanced CT
  Lucas et al., [@B78]                 33           18 healthy; 6 hypopituitarism; 9 chromophobe adenoma                                                                                                   None                                  None mentioned                                                                                                100 mg                                                                                                                                             100 mg bolus (1.5 h after 25g arginine infusion)                                                                                        No side effects mentioned
  Maricle et al., [@B79]               15           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                2 mg/kg                                                                                                                                            1 mg/kg/h                                                                                                                               An elevation in mood ratings was seen for all 15 patients. (Mood ratings were an average of 40 before infusion, 60 during, and 42 after infusion). Mean anxiety decreased during the infusion (from 57 initially to 38 during infusion, and then increased to 62 after the infusion). Emotional fluctuations were seen in all patients, while only a third of the patients had a history of probable mood swings
  Maricle et al., [@B80]               8            idiopathic PD (and Fluctuating motor response)                                                                                                         Carbidopa                             None mentioned                                                                                                2 mg/kg daily × 3 days                                                                                                                             1 mg/kg/h                                                                                                                               Effect on mood and anxiety was dose responsive. Six of 8 patients had mood response (increase in mood score greater than 20%) during high dose infusion. Reduction of anxiety began shortly after onset of high-dose infusion. Peak effect on anxiety occurred 30 min after infusion had been stopped and was followed by precipitous increase in anxiety. Patients had little insight into discrepancy between their subjective reports and how they appeared to observers during their dyskinetic and agitated, but relatively euphoric state
  Maricle et al., [@B81]               18           Idiopathic PD                                                                                                                                          None                                  Domperidone                                                                                                   2 mg/kg daily × 2 days                                                                                                                             1 mg/kg/h                                                                                                                               No significant side effects. Authors believe, "A significant mood response after a 2-day levodopa holiday supports the hypothesis that pharmacologic tolerance may be involved in this process and that sensitization may appear after a relatively brief period of abstinence form levodopa even in the first year of levodopa therapy"
  Marion et al., [@B82]                3            PD                                                                                                                                                     Benserazide                           None mentioned                                                                                                755--1750 mg/12 h                                                                                                                                  150 mg/10 min                                                                                                                           No significant side effects mentioned. The patients did not experience any major discomfort or inconvenience during the course of the infusions and were pleased with their improved motor performance. Infusions were given for 6 h on day 1, and 12 h on day 2. One patient had mild dyskinesia. The number of on-off switches decreased and the duration of "on" periods increased in all three patients during the infusion periods compared to oral therapy. IV infusion of levodopa (with PDI) can give reproducible periods of constant mobility in selected patients for up to 5 consecutive days. One patient felt a feeling of "euphoria" after initial infusion. Another patient had a symptomatic fall of blood pressure from 140/80 mm Hg to 70/30 mm Hg when rate was at 99 mg/h of levodopa, so the infusion rate was decreased to 60 mg/h
  Matussek et al., [@B83]              10           Depression and healthy subjects                                                                                                                        None mentioned                        None mentioned                                                                                                25--50 mg, 50--100 mg                                                                                                                              Not given                                                                                                                               Headache, nausea
  McGeer and Zeldowicz, [@B84]         10           PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                Not given                                                                                                                                          5 mg/min                                                                                                                                Three patients who were given L-Dopa intravenously experienced nausea when infusion rate increased to 5 mg/min; but all pts tolerated 2 mg/min with no noticeable side effects, except for one patient who reported light-headedness immediately following the infusion
  Metman et al., [@B86]                25           Advanced PD                                                                                                                                            Carbidopa                             None mentioned                                                                                                Max dose is 45--540 mg (15--180 mg/10 min × up to 3 doses)                                                                                         180 mg/10 min                                                                                                                           No side effects mentioned
  Metman et al., [@B85]                4            PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                413--483 mg (64 ± 5 mg/h × 7 h)                                                                                                                    69 mg/h                                                                                                                                 No side effects mentioned
  Metzel, [@B87]                       61           PD                                                                                                                                                     None mentioned                        MAO inhibitor                                                                                                 Not given                                                                                                                                          Not given                                                                                                                               No side effects mentioned. In some cases dopa was combined with a MAO-inhibitor
  Moorthy et al., [@B88]               8            Organic heart disease undergoing routine catheterization                                                                                               None mentioned                        None mentioned                                                                                                100--200 mg (avg. 144 mg)                                                                                                                          200 mg/10 min                                                                                                                           Nausea (5 pts), accompanied by vomiting (in 2 pts). The nausea was severe at 10--15 min after the start of the L-dopa infusion. Serious arrhythmias were not seen. Two patients had ventricular premature contractions. The effects on the cardiovascular system observed were slight. blood pressure showed a tendency to fall in some patients during the initial 5 min after injection and to rise later to values higher than the control values. No serious complications were seen. The authors\' observations seem to indicate that treatment with L-dopa is not particularly dangerous in patients with organic heart disease
  Mouradian et al., [@B90]             23           PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                Up to 11 days, 24 h/day                                                                                                                            1.8 mg/kg/h                                                                                                                             Maximum rate provided in Juncos et al. ([@B71]), who also give number of subjects as 28. No side effects
  Mouradian et al., [@B92]             4            Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                Optimal dose infusion (not quantified)                                                                                                             Optimal dose rate lasting at least 16 h                                                                                                 No side effects mentioned; no cardiovascular complications. There was no discernible alteration in the motor response to intravenous levodopa at any time during the period of physical activity
  Mouradian et al., [@B91]             29           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                200 mg                                                                                                                                             200 mg/10 min                                                                                                                           No side effects mentioned
  Mouradian et al., [@B89]             12           PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                1.0 ± 0.1 mg/kg/h × up to 12 days                                                                                                                  variable; apparently up to 200 mg/10 min as a loading dose                                                                              Minimal dyskinesias, with 1.0 mg/kg/h as the dyskinesia threshold dose
  Mure et al., [@B94]                  8            PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                1.13 ± 0.41 mg/kg/h (duration not reported)                                                                                                        Not given                                                                                                                               Doses titrated to achieve maximal Unified Parkinson\'s Disease Rating Score response without causing dyskinesia. No significant changes in regional cerebral blood flow
  Nardini et al., [@B95]               17           PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                25 mg                                                                                                                                              25 mg "slow infusion," 1.5 - 3 mg/kg/h                                                                                                  Asthenia, insomnia, anxiety, headache, increased "tensori," restlessness, disorientation and confusion. No side effects in arterial pressure, digestive problems, liver or renal function
  Nisijima et al., [@B97]              3            Neuroleptic malignant syndrome (NMS)                                                                                                                   None mentioned                        Two patients infused with dantrolene                                                                          50--100 mg/day                                                                                                                                     Not given                                                                                                                               No side effects mentioned. Symptoms of NMS decreased dramatically. Authors write, "Levodopa, particularly in injectable form, should be more positively used for pharmacotherapy in patients with NMS"
  Nutt et al., [@B110]                 9            Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                Total between 2200--7200 mg, (infusions were continued for 20--36 h)                                                                               110 mg/h with carbidopa, 200 mg/h without carbidopa                                                                                     Severe dyskinesia in one patient. The patients moved around the ward and exercised freely due to IV L-dopa. Eating a high-protein meal during levodopa infusion is associated with a decline in the clinical response to the infused levodopa without any alteration in the plasma concentration
  Nutt et al., [@B108]                 9            Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                Max 1250 mg                                                                                                                                        2.12 mg/kg/h                                                                                                                            Mild dyskinesia
  Nutt et al., [@B104]                 8            PD (with fluctuating response)                                                                                                                         Carbidopa                             None mentioned                                                                                                0.28--2.54 mg/kg                                                                                                                                   1.27 mg/kg/h                                                                                                                            Post-improvement worsening. Some mild dyskinesia
  Nutt et al., [@B109]                 27           PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                0, 0.4, 0.8, 1.6, 2.4 mg/kg/h × 2 h                                                                                                                2.4 mg/kg/h                                                                                                                             Mild dyskinesia
  Nutt et al., [@B101]                 19           PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                33.3 mg/kg/ 21 h                                                                                                                                   1.6 mg/kg/h                                                                                                                             Short infusions were well-tolerated, long infusions less so. Two subjects had dyskinesia during long infusion and two others suffered from confusion, although short infusions were well-tolerated by all subjects
  Nutt et al., [@B102]                 17           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                2 h (average 1.96 mg/kg, max 3.2 mg/kg)                                                                                                            Max: 1.6 mg/kg/h, mean: 0.98 mg/kg/h                                                                                                    2 patients developed nausea and one experienced lightheadedness (only during post-holiday levodopa infusions). In general, 2-h levodopa infusions were "well-tolerated," with no medical complications during the levodopa holiday
  Nutt et al., [@B103]                 16           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                2 mg/kg                                                                                                                                            mean 0.98 mg/kg/h                                                                                                                       Some nausea and lightheadedness
  Nutt et al., [@B99]                  11           Idiopathic PD (and fluctuating response)                                                                                                               Carbidopa                             None mentioned                                                                                                2 mg/kg                                                                                                                                            1.51 mg/kg/h                                                                                                                            Mild dyskinesia
  Nutt et al., [@B100]                 18           PD                                                                                                                                                     Carbidopa                             Domperidone                                                                                                   4 mg/kg total (2 mg/kg daily × 2 days)                                                                                                             1 mg/kg/h                                                                                                                               Levodopa therapy was able to restore tapping speed almost to normal
  Nutt et al., [@B106]                 12           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                2 or 3 mg/kg                                                                                                                                       1 or 1.5 mg/kg/h                                                                                                                        No side effects mentioned. Mood, anxiety, and blood pressure were measured at 30-min intervals for 7 h total, and there was no mention of any effects of levodopa on anxiety or blood pressure
  Nutt et al., [@B98]                  18           Idiopathic PD                                                                                                                                          Carbidopa                             Domperidone                                                                                                   4 mg/kg total (1 mg/kg/h × 4 h)                                                                                                                    1 mg/kg/h                                                                                                                               The same dose of L-Dopa produced progressively more severe dyskinesia with long-term L-dopa therapy but did not increase the duration of dyskinesia in patients. However, increasing the dose of L-dopa in subjects with dyskinesia does not increase the severity of dyskinesia but does increase the duration of dyskinesia
  Nutt and Nygaard, [@B105]            4            All 4 had DRD (dopa-responsive dystonia); 2 had PD in addition to DRD                                                                                  Carbidopa                             None mentioned                                                                                                2 mg/kg daily × 2 days                                                                                                                             1 mg/kg/h                                                                                                                               No side effects mentioned. "In one subject, two doses of levodopa and a night\'s sleep abolished her dystonia and restored normal tapping rate"
  Nutt and Woodward, [@B107]           23           Idiopathic PD (and fluctuating response)                                                                                                               Carbidopa                             None mentioned                                                                                                3.0--13.2 mg/kg (0.5--2.2 mg/kg/h × 6 h)                                                                                                           2.2 mg/kg/h                                                                                                                             2 patients exhibited a brief burst of mobility and dyskinesia lasting minutes. Generally, with the onset of mobility, the patients had a brief burst of tremor, or tremor mixed with dyskinesia, and then became mildly dyskinetic
  Ogawa et al., [@B111]                1            PD                                                                                                                                                     None mentioned                        Dai-kenchu-tou (5-HT3 receptor agonist)                                                                       Not mentioned                                                                                                                                      75 mg/kg daily boluses, duration not reported                                                                                           IV levodopa was used as a treatment for neuroleptic malignant syndrome
  Oishi et al., [@B112]                20           Parkinsonism (PD, vascular parkinsonism)                                                                                                               None mentioned                        None mentioned                                                                                                50 mg                                                                                                                                              50 mg bolus                                                                                                                             No side effects mentioned
  Pare and Sandler, [@B113]            3            Depression candidates for ECT who were responsive to Iproniazid                                                                                        None mentioned                        Iproniazid                                                                                                    12.5--137.5 mg (25 mg--275 mg racemic)                                                                                                             275 mg bolus of DL-DOPA                                                                                                                 No side effects mentioned. DL-DOPA was used
  Pazzagli and Amaducci, [@B114]       11           PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                60 mg, 90 mg, or 120 mg                                                                                                                            Not given                                                                                                                               Hypotension, nausea, vomiting, somnolence, and mild sedation accompanied by feeling euphoric
  Peppe et al., [@B115]                5            PD                                                                                                                                                     Carbidopa                             Domperidone                                                                                                   770 mg/day × 5 days, (given 110 mg/kg/h × 7 h)                                                                                                     110 mg/h (mean 70 mg/h)                                                                                                                 No side effects mentioned
  Poewe, [@B116]                       Not given    Not given                                                                                                                                              None mentioned                        None mentioned                                                                                                Not given                                                                                                                                          not given                                                                                                                               No side effects mentioned. From a table entry in a review article
  Pullman et al., [@B117]              10           5 PD and 5 healthy                                                                                                                                     Carbidopa                             None mentioned                                                                                                Not given                                                                                                                                          Varied rates from high, middle, and low (actual dose not specified)                                                                     No side effects mentioned
  Puritz et al., [@B118]               13           6 healthy; 7 progressive autonomic failure and multiple system atrophy (MSA)                                                                           None mentioned                        None mentioned                                                                                                99.875 mg                                                                                                                                          1.175 mg/min                                                                                                                            No subjects experienced adverse effects during the infusion although one vomited after discontinuation of L-dopa. For one dosage and rate: change in AVP (plasma arginine vasopressin), blood pressure and heart rate are given. No significant effects of L-Dopa on mean blood pressure in normal subjects, but lowered blood pressure of MSA patients. No effect heart rate or AVP levels in basal state. Author suggests "L-Dopa should not be prescribed for patients with MSA"
  Quinn et al., [@B119]                3            PD                                                                                                                                                     Benserazide                           None mentioned                                                                                                Not given (only that treatment was given for about 8 h at unspecified rate)                                                                        Not given                                                                                                                               No side effects mentioned. The patients with severe on-off fluctuations had dramatic benefit. Authors write, "Intravenous levodopa infusion obviously overcomes many of the problems of intermittent oral treatment"
  Quinn et al., [@B120]                10           PD                                                                                                                                                     Carbidopa or benserazide              None mentioned                                                                                                Variable; highest total dose appears to be 187 mg/h × 8.8 h × 12 doses                                                                             150 mg bolus in ≥2 subjects; all subjects received 100--200 mg over 10 min, then up to 187 mg/h (mean 125 mg/h)                         Pulse and blood pressure fell, but to the same degree as with oral levodopa; "slight and transient" postural faintness (orthostasis); coldness of the limbs; nausea and vomiting; dyskinesias. No patient complained of palpitations during the infusions, and no arrhythmias were detected. Authors assert, "Continuous intravenous infusion of levodopa turns out to be the most effective way of abolishing the off state during a substantial period of the day"
  Rinne and Sonninen, [@B122]          36           Idiopathic PD (24) and post-encephalitic PD (12)                                                                                                       None                                  None mentioned                                                                                                1.5 mg/kg                                                                                                                                          1.5 mg/kg/10 min                                                                                                                        Pulse and blood pressure changes were comparable between levodopa and placebo. Common adverse effects included nausea (47%), vomiting (31%), vertigo (19%), headache (33%), sweating (44%), and anxiety (22%); frequency of adverse effects not reported with placebo
  Roberts et al., [@B123]              8            Normal                                                                                                                                                 Carbidopa                             None mentioned                                                                                                50 mg                                                                                                                                              50 mg/5 min                                                                                                                             None mentioned
  Robertson et al., [@B124]            28           12 healthy elderly and 16 healthy young subjects                                                                                                       Both with and without carbidopa       None mentioned                                                                                                50 mg bolus                                                                                                                                        50 mg bolus/5 min                                                                                                                       None mentioned
  Rodriguez et al., [@B125]            14           Asymmetric PD                                                                                                                                          Carbidopa                             Domperidone. Apomorphine given subcutaneously                                                                 960 mg to 2200 mg (60--100 mg/h × 16--22 h)                                                                                                        250 mg/h (for short infusion). Up to 100 mg/h (for long infusion)                                                                       None mentioned
  Rosin et al., [@B127]                1            Idiopathic PD and carcinoma of the rectum                                                                                                              Carbidopa                             None mentioned                                                                                                4320 mg highest total dose for a day (given between 1200 and 4320 mg/day for 7 days)                                                               180 mg/h                                                                                                                                No side effects or adverse effects: no "undue" abdominal distention, nausea, vomiting, cardiac arrhythmia, or hypotension
  Ruggieri et al., [@B128]             20           Idiopathic PD                                                                                                                                          Carbidopa                             Domperidone                                                                                                   (360--1200 mg/day) × 3 days                                                                                                                        1200 mg/day x 3 days                                                                                                                    The patients were given constant IV L-dopa infusion for 12 h × 3 days. Mild somnolence, nausea, and occasional vomiting were the only side effects reported. There was an increase in blood pressure (probably due to domperidone). Maximum optimal drug rate ranged from 30--104 mg/h with mean 53.5 mg/h
  Sage and Mark, [@B129]               1            PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                240 mg/day (during nighttime)                                                                                                                      30 mg/h                                                                                                                                 No side effects mentioned. Oral carbidopa/levodopa was given during the daytime while IV levodopa was administered at night. Nighttime infusions produced immediate benefit of a good night\'s sleep, and nighttime levodopa infusions also reduced patient\'s daytime motor fluctuations. Authors suggest the levodopa infusion rate required to produce the best results was between 40 and 45 mg/h
  Sasahara et al., [@B131]             5            PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                50 mg                                                                                                                                              50 mg/20 min                                                                                                                            No side effects mentioned
  Schuh and Bennett, [@B132]           6            Advanced idiopathic PD                                                                                                                                 Carbidopa                             None mentioned                                                                                                57.6 mg/kg, (given 24 h/day × 3--8 days)                                                                                                           2.4 mg/kg/h                                                                                                                             L-Dopa induced dyskinesia, but only occurs because of the progression of PD. No other side effects mentioned
  Shinoda et al., [@B133]              1            PD                                                                                                                                                     None mentioned                        None mentioned                                                                                                75 mg                                                                                                                                              50 mg bolus                                                                                                                             Patient developed neuroleptic malignant syndrome (NMS) due to underdosing of IV levodopa as a result of dilution in extracorporeal circulation during open heart surgery
  Shoulson et al., [@B134]             5            PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                Not given (duration of 3 h at unspecified rate)                                                                                                    Not given                                                                                                                               No side effects mentioned. No significant changes in pulse rate or blood pressure occurred
  Siddiqi et al., [@B135]              29           Tourette syndrome and healthy controls                                                                                                                 Carbidopa                             None                                                                                                          0.6426 mg/kg                                                                                                                                       2.882 × 10^−5^ × (140--age) mg/kg/min                                                                                                   No significant difference in pulse, blood pressure, or orthostatic change between IV levodopa and placebo when co-administered with carbidopa
  Skalabrin et al., [@B136]            9            Advanced PD                                                                                                                                            Carbidopa                             None mentioned                                                                                                Not given                                                                                                                                          2.6--3.0 mg/kg/h                                                                                                                        Doses escalated until a maximum of 3.0 mg/kg/h infusion rate was achieved, OR the subject experienced maximum dyskinesia, or developed nausea or hypotension
  Sohn et al., [@B137]                 42           PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                36--150 mg                                                                                                                                         150 mg/10 min                                                                                                                           No side effects mentioned
  Souvatzoglou et al., [@B138]         25           Healthy                                                                                                                                                None mentioned                        None mentioned                                                                                                1 mg, 5 mg, 12.5 mg, 25 mg, or 100 mg                                                                                                              5 mg/ml L-dopa infused, blood samples drawn at 10 min intervals over 3--4 h. (therefore the lowest max rate possible was 5 mg/ml/min)   2 cases at 100 mg of mild nausea lasting 5--10 min. In no instance were any cardiac effects observed. Serum growth hormone is stimulated by 25 mg IV L-dopa
  Stocchi et al., [@B139]              18           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                1080--3750 mg total (360--1250 mg/day for 3 days)                                                                                                  1250 mg/day × 3 days                                                                                                                    No side-effects, except for a mild somnolence during the first day, were recorded. Blood pressure, cardiac electric morphology, and rhythm did not change significantly during the study. Authors argue IV infusion could be a precious form of rating the real single individual\'s L-dopa needs. They write, "L-dopa infusion remains a good technique in the overall evaluation of the parkinsonian patient and indispensable in particular situations like post-operative recovery and intensive care"
  Stocchi et al., [@B140]              9            PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                100 up to ≥600 mg/days                                                                                                                             200 mg boluses or 400 mg/h. For 3 subjects: "optimum rate" for 12 h × 3 days                                                            No side effects mentioned. Blood pressure and pulse were assessed every 15 min, and no mention was made of any changes to either blood pressure or pulse
  Sunami et al., [@B141]               1            Akathisia                                                                                                                                              None mentioned                        None mentioned                                                                                                25 mg/day × 8 days, followed by lower infusions                                                                                                    25 mg/day                                                                                                                               No side effects mentioned. Authors believe IV levodopa treatment "would be useful in reducing the persistent neurotoxicity (lethargy, hypersomnia, depression, agitation, akathisia, and confusion) associated with interferon-alpha"
  Takeuchi et al., [@B143]             8            Healthy                                                                                                                                                None mentioned                        None mentioned                                                                                                50 mg                                                                                                                                              50 mg for \>10 min                                                                                                                      Study of mechanisms of orthostatic hypotension in L-dopa treated PD. At rest, the systolic blood pressure was significantly lowered by L-dopa administration, but diastolic blood pressure, heart rate, and calf blood flow were not significantly altered by L-dopa administration. Spontaneous muscle sympathetic nerve activity was significantly higher than that before administration. Results support hypothesis that L-dopa and/or its metabolites act on peripheral blood vessels at sympathetic nerve terminal, thereby inducing orthostatic hypotension
  Takubo et al., [@B144]               32           Malignant syndrome (MS)                                                                                                                                Some subjects given unspecified PDI   None mentioned                                                                                                2440 mg/day (for patient before study began)                                                                                                       Not given                                                                                                                               No side effects mentioned. Suggests the following dosages of IV levodopa in the treatment of malignant syndrome: 300--600 mg/24 h or 100--200 mg/3 h three times a day
  Tedroff et al., [@B146]              6            PD and healthy                                                                                                                                         Benserazide                           None mentioned                                                                                                0.9 mg                                                                                                                                             0.9 mg bolus                                                                                                                            No side effects mentioned
  Tedroff et al., [@B145]              8            Idiopathic PD                                                                                                                                          Benserazide                           None mentioned                                                                                                200 mg                                                                                                                                             200 mg/6 min                                                                                                                            No side effects mentioned; brain uptake of \[β-^11^C\]-L-DOPA was inversely correlated to the sum of large neutral amino acids in plasma
  Tedroff et al., [@B147]              10           PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                3 mg/kg                                                                                                                                            0.5 mg/kg/min bolus for 5 min                                                                                                           Before the study, one patient was excluded due to levodopa-induced nausea. Authors write, "levodopa is still the most effective symptomatic treatment for PD, and compared with the various dopamine agonists available, is well-tolerated by most patients. The finding that the capacity for levodopa to produce increased synaptic dopamine levels is most profound in the more denervated regions of the striatum means that levodopa is acting preferentially at the site of dopaminergic denervation"
  Torstenson et al., [@B148]           10           Idiopathic PD                                                                                                                                          Carbidopa                             None mentioned                                                                                                5 mg/kg (2 mg/kg + 2 mg/kg/h × 1.5 h)                                                                                                              0.5 mg/kg/min over 4 min as bolus; then 2 mg/kg/h                                                                                       No side effects mentioned
  Tzavellas and Umbach, [@B149]        125          PD                                                                                                                                                     None mentioned                        Propylhexadrine (amphetamine)                                                                                 Not given                                                                                                                                          Not given                                                                                                                               No side effects mentioned. Subjects received a combination of L-dopa and propyl-hexedrin (MAO inhibitor)
  Umbach, [@B150]                      Not given    Not given                                                                                                                                              None mentioned                        Amphetamine                                                                                                   Not given                                                                                                                                          Not given                                                                                                                               No side effects for L-dopa alone. Reported side effects are caused by combination treatment with amphetamines. L-dopa and amphetamine treatment of akinetic Parkinsonism patients with and without stereotaxic surgery. It is not clear how many were treated only with L-Dopa
  Umbach and Baumann, [@B151]          35           30 PD, 5 controls                                                                                                                                      None mentioned                        None mentioned                                                                                                100 mg in 13 patients and 100 mg in 17 patients                                                                                                    Not given                                                                                                                               Patients after stereotaxic surgery. Specific L-dopa side effects are not mentioned, but it is said that higher doses caused more severe side effects
  Umbach and Tzavellas, [@B152]        30           PD                                                                                                                                                     None mentioned                        Propylhexadrine (amphetamine)                                                                                 50 mg                                                                                                                                              Not given                                                                                                                               L-Dopa alone caused drop in blood pressure
  Verhagen Metman et al., [@B154]      6            Idiopathic PD                                                                                                                                          Carbidopa                             Dextromethorphan                                                                                              up to 65 ± 14 mg                                                                                                                                   Not given                                                                                                                               No side effects mentioned. Brief IV infusions (10 min each, 4 h for a total of 9--12 infusions)
  Verhagen Metman et al., [@B153]      14           PD                                                                                                                                                     Carbidopa                             None mentioned                                                                                                ≥150 mg                                                                                                                                            150 mg/10 min                                                                                                                           No side effects mentioned
  Voller, [@B155]                      180          PD                                                                                                                                                     None mentioned                        In unspecified number of patients, MAO inhibitors (isocarboxazid 10 mg TID or nialamide 25 mg BID)            25 mg twice per week                                                                                                                               Not given                                                                                                                               Increase of PR interval (on electrocardiogram), tachycardia, sweating, nausea. All these were mild and transient so that no experiment was interrupted
  Worth et al., [@B156]                6            Healthy                                                                                                                                                None mentioned                        None mentioned                                                                                                840 μg/kg                                                                                                                                          7 μg/kg/min                                                                                                                             Mean plasma renin activity fell by 50%; significant increase in urinary sodium excretion and effective renal plasma flow; mean diastolic blood pressure fell with no reflex tachycardia. Mean diastolic pressure fell on infusion of L-dopa. Trends toward fall in mean systolic pressure and rise in mean pulse rate on infusion of L-dopa, but these were not significantly different from changes occurring on saline infusion
  Zsigmond et al., [@B157]             10           PD                                                                                                                                                     None                                  None                                                                                                          281.25 mg                                                                                                                                          375 mg/h for 45 min                                                                                                                     No side effects mentioned. In 2 patients who had previously discontinued oral levodopa/carbidopa due to nausea, high doses of IV levodopa were well-tolerated and relieved symptoms
  Total references 142                 Total 2760                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

*Summary of published studies reporting IV levodopa use in humans, 1959 to early 2015*.

Concomitantly administered peripheral decarboxylase inhibitors included carbidopa and benserazide. PDIs affected clearance and volume of distribution (as mentioned above), minimized gastrointestinal symptoms, and allowed subjects to be given lower doses of levodopa. Other concomitant drugs are listed, to help explain any side effects that might be caused by concomitant drug administration or an interaction with levodopa rather than by levodopa alone. These include adenosine receptor antagonists (istradefylline, tozadenant \[SYN115\], aminophylline, caffeine), stimulants (amphetamines, methylphenidate), dopamine receptor agonists (apomorphine, terguride, SKF38393), monoamine oxidase (MAO) inhibitors, dextromethorphan, estradiol, paroxetine, and dantrolene.

A variety of neurological, psychiatric, cardiovascular, and other physiological effects of levodopa were monitored (see Table [1](#T1){ref-type="table"}). There were no reported deaths. There were no instances of psychosis, even when attempting to elicit it in susceptible subjects (Goetz et al., [@B52]). There were also no life-threatening events (serious adverse effects) following IV levodopa administration at high doses, regardless of whether a PDI was co-administered. With co-administration of a PDI, the dosage range causing side effects (mainly nausea and asymptomatic hypotension) was 45--150 mg as a single bolus or infusions of 0.5--2.0 mg/kg/h. Without a co-administered PDI, side effects were reported with a bolus of 60--200 mg or an infusion of 1.5--3.0 mg/kg/hr. Side effects were more likely with higher doses, but other factors such as age, sex, disease severity, and prior treatment also played a role in side effects of levodopa.

Other than these side effects found at high doses, several milder or less frequent side effects were reported. These primarily included mild autonomic changes (orthostasis and tachycardia), psychiatric changes (sedation, anxiety, insomnia, and improvement in mood), and neurologic effects (improvements in tics, REM sleep changes, subjective weakness, headaches, and increased dyskinesias). Various other effects were noted in isolated reports (listed in Table [3](#T3){ref-type="table"}). It is important to note that both side effects and efficacy depended strongly on subject factors including gender, age, past treatment, and disease state. Also, dsykinesia was mentioned as a side effect only in patients with PD, and most often in those with a long history of previous levodopa treatment.

Motor benefits of levodopa in PD have been demonstrated conclusively. Additional reported benefits of IV levodopa treatment in PD included improved sleep (Hardie et al., [@B57]) and attenuation of early morning akinesia or dystonia (Juncos et al., [@B72]). In other patient groups, benefits of IV levodopa included improvement of the comatose state in hepatic encephalopathy (Abramsky and Goldschmidt, [@B1]) and improvement in depressive and somatoform symptoms (Ingvarsson, [@B67]). One report found it more effective than dantrolene for treating neuroleptic malignant syndrome (Nisijima et al., [@B97]). More recently, IV levodopa treatment was found to alleviate the neuropsychiatric adverse effects associated with interferon-alpha, namely lethargy, hypersomnia, depression, agitation, akathisia, and confusion (Sunami et al., [@B141]).

Discussion {#s4}
==========

The existing literature strongly supports the safety of IV levodopa, which has been used in humans for more than half a century (Pare and Sandler, [@B113]). IV levodopa has been administered to over 2700 human subjects. Despite infusion rates as high as 5.0 mg/kg/h and boluses as large as 200 mg, there are no recorded instances of death or of other serious adverse effects of IV levodopa, nor have there been documented cases of other serious side effects, such as psychosis, that might limit its use in humans. Milder side effects, the most significant of which are nausea and vomiting, were most prominent with rapid infusions in the range of 1--2 mg/kg or 100--200 mg over less than 15 min (Bruno and Bruno, [@B25]; Fehling, [@B41]; Rinne and Sonninen, [@B122]; Moorthy et al., [@B88]; Quinn et al., [@B120]; Black et al., [@B15]).

These conclusions are supported by safety data from other species. The Registry of Toxic Effects of Chemical Substances reports the lowest published toxic dose of levodopa in any non-human species as 2.5 mg/kg, referring to a subtle behavioral effect on a learning measure in a mouse (NIOSH and Biovia, [@B96])[^1^](#fn0001){ref-type="fn"}. The lowest IV levodopa dose that was lethal to half of subjects (LD50) was "\>100 mg/kg" in rats. In mice, the LD50 ranges from 450 mg/kg (administered intravenously) to 4449 mg/kg (administered subcutaneously). Typical human doses are in the range of only 1 mg/kg; thus, human studies with IV levodopa administer doses substantially lower than those dangerous to nonhuman mammals.

In summary, IV levodopa has similar efficacy and side effects as oral levodopa (Connolly and Lang, [@B31]) and dopamine agonists (Bonuccelli and Ceravolo, [@B18]). These include gastrointestinal (nausea, vomiting, and abdominal discomfort) and neuropsychiatric effects (sedation, dyskinesias). Nausea and orthostatic hypotension, side effects of both IV and oral levodopa, are largely blocked by PDIs and are less common in patients accustomed to dopamimetic treatment. The other side effects are infrequent and neither serious nor life-threatening (Connolly and Lang, [@B31]). When given with adequate PDI pretreatment, IV levodopa has minimal if any cardiovascular effects (Siddiqi et al., [@B135]).

The safety of IV levodopa is important for patients but also for regulatory review. Changing the route of administration of any drug in a study traditionally necessitates submitting an IND application if changing the route of administration "significantly increases the risks ... associated with the use of the drug product" \[§21 CFR 312.2(b)(iii)\]. The data from our review of the literature suggest that IV administration of levodopa does not significantly increase the associated risks of levodopa in comparison to oral administration. In summary, studies conducted throughout the past half century support the safety of IV levodopa administration in human patients.
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